Regenics Welcomes Brynjólfur Gísli Eyjólfsson as New Chair
Regenics AS, a notable biotech firm from Norway, has recently appointed Brynjólfur Gísli Eyjólfsson to the vital position of Chair of the Board of Directors. This strategic decision marks an exciting chapter in the company’s journey as it focuses on innovative marine-based wound care products.
A Wealth of Experience in Leadership
Brynjólfur Eyjólfsson is known for his extensive background in the blue economy and investment sectors, currently serving as Fund Manager for the IS Haf Fund. Notably, this fund is recognized as the largest investor in Nordic Blue ehf., which holds a significant stake in Regenics. This background not only enriches the board but also strengthens the company’s strategic direction in an ever-evolving industry.
Collaborating for Success
Joining Mr. Eyjólfsson on the board are seasoned professionals including Runhild Gammelsæter, Harald Nordal, Tore H. Rasmussen, and Beat Moser. The combined expertise of these individuals spans multiple domains such as medical technology, regulatory affairs, clinical research, and commercialization, forming a robust foundation for Regenics’s future endeavors.
Eyjólfsson’s Vision for Regenics
Upon his appointment, Brynjólfur expressed his enthusiasm, stating, "It is an honor to take on the role of Chair at Regenics. We believe the company’s marine-based platform and its lead product have significant clinical and commercial potential." His vision is to navigate the company into clinical development phases with the backing of Nordic Blue and Haf Investments.
Gratitude for Past Leadership
Regenics also acknowledges the contributions of its outgoing board chair, Jan A. Alfheim, who has played a critical role in steering the company for the past four years. His leadership has laid the groundwork for continued innovation and growth within the organization.
Innovative Solutions at the Core of Regenics
Regenics is at the forefront of developing next-generation wound care solutions derived from marine bioactives found along the Norwegian coast. Their proprietary HTX™ technology, sourced from salmon roe, underpins Collex®, which is currently advancing through preclinical studies targeting partial-thickness burns and chronic wounds.
The Brains Behind Eyjólfsson
Brynjólfur Gísli Eyjólfsson is not just an executive; he boasts over 25 years of rich experience in seafood operations and financial management, having held significant roles at companies like PwC and Brim. His current focus is on managing the Haf Investments fund that prioritizes sustainable ventures in the blue economy, particularly in the Arctic region.
Partnerships Fueling Growth
Haf Investments, under the banner of IS Haf Fjárfestingar slhf., is a progressive private equity fund that emphasizes sustainable investments across seafood, marine biotechnology, and sectors related to the blue economy. As the largest stakeholder in Nordic Blue hf., they play a pivotal role in supporting innovative companies like Regenics.
Frequently Asked Questions
What is Brynjólfur Gísli Eyjólfsson's experience?
Brynjólfur has over 25 years in seafood operations and financial management, previously leading at notable firms like PwC.
What is the focus of Regenics AS?
Regenics specializes in developing advanced wound care products, particularly those utilizing marine bioactives.
How does Haf Investments contribute to Regenics?
As the largest investor in Nordic Blue hf., Haf Investments significantly supports Regenics's initiatives and growth strategies.
What technology does Regenics use?
The company primarily employs its proprietary HTX™ technology, derived from salmon roe, to create innovative wound care solutions.
Why is Jan A. Alfheim recognized in this announcement?
Regenics thanks Jan A. Alfheim for his leadership over the past four years, guiding the company through pivotal phases.
